Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>
Збережено в:
| Автор: | |
|---|---|
| Інші автори: | , , , , , , , , , |
| Опубліковано: |
2025
|
| Предмети: | |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| _version_ | 1851485229269647360 |
|---|---|
| author | Monica M. Mita (21585118) |
| author2 | Alain C. Mita (21585121) Bradley J. Carver (18491067) James M. Shanahan (18491064) Benjamin A. Mayes (18491052) Pierre J. Dufour (18491061) David Browning (21585124) Alfred Anderson-Villaluz (21585127) John S. Petersen (18491055) David J. Turnquist (18491058) Peter Cornelius (18491049) |
| author2_role | author author author author author author author author author author |
| author_facet | Monica M. Mita (21585118) Alain C. Mita (21585121) Bradley J. Carver (18491067) James M. Shanahan (18491064) Benjamin A. Mayes (18491052) Pierre J. Dufour (18491061) David Browning (21585124) Alfred Anderson-Villaluz (21585127) John S. Petersen (18491055) David J. Turnquist (18491058) Peter Cornelius (18491049) |
| author_role | author |
| dc.creator.none.fl_str_mv | Monica M. Mita (21585118) Alain C. Mita (21585121) Bradley J. Carver (18491067) James M. Shanahan (18491064) Benjamin A. Mayes (18491052) Pierre J. Dufour (18491061) David Browning (21585124) Alfred Anderson-Villaluz (21585127) John S. Petersen (18491055) David J. Turnquist (18491058) Peter Cornelius (18491049) |
| dc.date.none.fl_str_mv | 2025-06-23T09:00:21Z |
| dc.identifier.none.fl_str_mv | 10.1158/2767-9764.29381362 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_S2_from_A_Phase_1_Safety_Study_of_Evexomostat_SDX-7320_in_Patients_with_Late-Stage_Cancer_An_Antiangiogenic_Insulin-Sensitizing_Drug_Conjugate_Targeting_METAP2/29381362 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials |
| dc.title.none.fl_str_mv | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_f5a6a8e4b14d1e4324fee6e3bba4d2f6 |
| identifier_str_mv | 10.1158/2767-9764.29381362 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/29381362 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2Monica M. Mita (21585118)Alain C. Mita (21585121)Bradley J. Carver (18491067)James M. Shanahan (18491064)Benjamin A. Mayes (18491052)Pierre J. Dufour (18491061)David Browning (21585124)Alfred Anderson-Villaluz (21585127)John S. Petersen (18491055)David J. Turnquist (18491058)Peter Cornelius (18491049)CancerCancer Detection and DiagnosisTherapeutic Research and DevelopmentClinical Research and TrialsBiomarkersProtein biomarkersPharmacologyPharmacokinetics and pharmacodynamicsPhase I Clinical Trials<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>2025-06-23T09:00:21ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.29381362https://figshare.com/articles/figure/Figure_S2_from_A_Phase_1_Safety_Study_of_Evexomostat_SDX-7320_in_Patients_with_Late-Stage_Cancer_An_Antiangiogenic_Insulin-Sensitizing_Drug_Conjugate_Targeting_METAP2/29381362CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/293813622025-06-23T09:00:21Z |
| spellingShingle | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 Monica M. Mita (21585118) Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials |
| status_str | publishedVersion |
| title | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| title_full | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| title_fullStr | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| title_full_unstemmed | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| title_short | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| title_sort | Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 |
| topic | Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials |